WO1996039187A1 - Method for treating molluscum contagiosum resulting from hiv infection - Google Patents
Method for treating molluscum contagiosum resulting from hiv infection Download PDFInfo
- Publication number
- WO1996039187A1 WO1996039187A1 PCT/US1996/009192 US9609192W WO9639187A1 WO 1996039187 A1 WO1996039187 A1 WO 1996039187A1 US 9609192 W US9609192 W US 9609192W WO 9639187 A1 WO9639187 A1 WO 9639187A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- cells
- patient
- monoclonal antibodies
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 208000008588 molluscum contagiosum Diseases 0.000 title claims abstract description 12
- 208000031886 HIV Infections Diseases 0.000 title description 44
- 208000037357 HIV infectious disease Diseases 0.000 title description 19
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title description 19
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 82
- 238000001802 infusion Methods 0.000 claims abstract description 39
- 230000003902 lesion Effects 0.000 claims description 20
- 210000004408 hybridoma Anatomy 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 51
- 239000000427 antigen Substances 0.000 abstract description 29
- 102000036639 antigens Human genes 0.000 abstract description 29
- 108091007433 antigens Proteins 0.000 abstract description 29
- 238000011282 treatment Methods 0.000 abstract description 28
- 208000015181 infectious disease Diseases 0.000 abstract description 26
- 201000010099 disease Diseases 0.000 abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 25
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 83
- 210000001744 T-lymphocyte Anatomy 0.000 description 50
- 208000030507 AIDS Diseases 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 210000004698 lymphocyte Anatomy 0.000 description 17
- 210000004970 cd4 cell Anatomy 0.000 description 16
- 230000002101 lytic effect Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 102100022339 Integrin alpha-L Human genes 0.000 description 11
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 230000006872 improvement Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 206010061598 Immunodeficiency Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 6
- 208000029462 Immunodeficiency disease Diseases 0.000 description 6
- 241000282579 Pan Species 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000007813 immunodeficiency Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 206010012434 Dermatitis allergic Diseases 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 5
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 5
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 5
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- 206010010144 Completed suicide Diseases 0.000 description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 4
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 201000000317 pneumocystosis Diseases 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 229940033330 HIV vaccine Drugs 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000003367 Hypopigmentation Diseases 0.000 description 2
- 239000012480 LAL reagent Substances 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 230000003425 hypopigmentation Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010044583 Bartonella Infections Diseases 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 101100386910 Caenorhabditis elegans laf-1 gene Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101001022957 Homo sapiens LIM domain-binding protein 1 Proteins 0.000 description 1
- 101001022948 Homo sapiens LIM domain-binding protein 2 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100035113 LIM domain-binding protein 2 Human genes 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 101001040747 Mus musculus Guanine nucleotide-binding protein-like 3 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241000565661 Neohelix albolabris Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 206010004145 bartonellosis Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 210000003515 double negative t cell Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- RCRODHONKLSMIF-UHFFFAOYSA-N isosuberenol Natural products O1C(=O)C=CC2=C1C=C(OC)C(CC(O)C(C)=C)=C2 RCRODHONKLSMIF-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates generally to methods for treating
- HIV immunodeficiency virus
- T-lymphocytes or their lytics in order to inhibit or treat HIV and related
- the present invention also includes a method of
- HIV immunodeficiency virus
- HIV human immunodeficiency virus
- CTL cytotoxic T-lymphocytes
- CD3 and CD4 antigens CD4+ T-lymphocytes
- HIV immunodeficiency virus
- CD4 + cells the number of cells infected is inadequate to account for
- CTL's are beneficial for those infected with HIV since it is believed
- CTL's help control the infection, i.e., CTL's are believed to be
- lymphocyte population that includes CTL's.
- HIV-infected humans have an anti-self, anti-CD4 CTL in
- HIV-infected chimpanzees This is significant because HIV infection
- T cell-monocyte adhesion pathways are important in HIV
- CD18-ICAM-1 results in greater than 90% inhibition of HIV-1
- lymphocytes CTL and their target cells.
- CTL lymphocytes
- HIV-infected chimpanzees have circulating CTL that lyse uninfected
- CD4+ T cells Because HIV-infected chimpanzees do not develop HIV
- HIV vaccine studies have shown that reducing CTL's causes the
- the present invention is based on the deduction that the reason CD4 counts go down in the first place as a
- T-lymphocyte is overcome according to the teachings of the present
- S6F1 mouse antibodies utilizes monoclonal S6F1 mouse antibodies (S6F1 mAb) directed
- CD4+ T lymphocytes from the peripheral blood of some adults with
- RNA persisted thereby indicating that the newly circulating cells are
- THF thymic humoral factor
- Another primary objective is to neutralize HIV-producing
- FIGURE 1 is a schematic representation of AIDS pathogenesis
- FIGURE 2 is a schematic representation of a S6F1 monoclonal
- FIGURE 3 illustrates the placement of antigen and control on a
- FIGURE 4 shows mean T cell/mm 3 v. weeks since infusion of
- FIGURES 5(a)-(d) show the results of several patients treated in
- FIGURE 6 shows the results of a patient with advanced HIV
- FIGURE 7 compares the results of treatment of S6F1 mAb
- FIGURE 8 illustrates response to second infusion in accordance
- FIGURE 9 shows the arithmetic mean of CD8% and CTL% of T
- TTL's T-lymphocytes
- CTL kills foreign cells (such as bacteria, fungus, viruses, cancer or the
- CTL's belong to a group of lymphocytes that carry a CD8
- HIV vaccine studies have shown that reducing CTL's causes
- S6F1 mouse antibodies (S6F1 mAb) are directed against an epitope of LFA-1 .
- S6F1 mAb is directed against an epitope of LFA-1 .
- lymphocytes as contrasted with suppressor CD8 + T cells.
- present invention is not limited to the use of mouse antibodies.
- LFA-1 LFA-1
- ICAM monoclonal antibodies are also directed against the
- FIGURE 1 is a schematic representation of what is believed to
- these cells carry various known antigens
- DR including, without limitation, DR, CD8, LFA-1 , ICAM and TCR-1 .
- cells also include one or more lytics which are chemical compounds
- lytics used to attack the target cell; such lytics also include antigens.
- the present invention overcomes the destructive action of the
- monoclonal antibody is an antibody that is made from one cell so that
- FIGURE 2 a representation is shown of the
- anti-self, anti-CD4 CTL are produced in the conventional manner and
- the present invention is intended to cover all such elements
- monoclonal antibodies are infused.
- the daily regimen is preferably
- an effective immune response will typically mean that the
- the patient's skin has an improved delayed cutaneous hypersensitivity
- monoclonal antibodies are typically supported in a suitable carrier such as
- the infusion may be effected using a conventional syringe
- the present invention is that it provides a method of neutralizing the
- the HIV disease can be transformed
- S6F1 refers to a mouse antibody directed against an epitope of
- LAF-1 and ICAM refer to monoclonal
- HIV could be cultured from his blood cells
- the patient was given about 68
- the AIDS virus could no longer be
- the dosage range varies from about 0.01 to about 1 .0
- PCP pneumocystis carinii pneumonia
- S6F1 LDB1 1 LDH10 One suitable S6F1 clone, S6F1 LDB1 1 LDH10, is disclosed in
- T cell phenotypes were enumerated by a 3-color flow cytometry
- Becton-Dickinson are suitable for use in accordance with the method
- HIV RNA was measured by polymerase chain reaction (PCR) in
- RNA guanidine/plant chloroform. The purified RNA was divided into two
- Negative controls were of two types: blanks with
- the response to an antigen is positive if, and only
- lymphocyte counts or functions are lymphocyte counts or functions.
- Each patient was infused with about 7 mg (approximately 0.1
- FIGURES 5(a)-(c) show the results for three patients with early
- FIGURE 5(d) illustrates the
- HIV RNA will necessarily increase when a patient is
- FIGURE 6 illustrates the results for a patient with more
- Thymic humoral factor has been reported to increase CD4 count and improve
- FIGURE 7 shows the results of a patient who had no detectable
- CD3 + CD4-CD8- T lymphocytes may offer little protection against
- This patient had a 2-log increase in HIV RNA
- HAMA human anti-mouse antibodies
- the patient was reinfused using a single dose of 7 mg as described in
- Example 2 At the time of reinfusion, the patient had a marked CD4 +
- FIGURE 6 did not exhibit replacement of double-marked T cells when
- FIGURE 7 Within two weeks of being reinfused, the patient being
- HAMA may also avoided by removing the heavy chains in
- human antibodies are suitable for use in accordance with the
- FIGURE 6 suggest that the CD8 + T cell significance is not yet
- lymphocytes at all for greater than three months and there were no
- HIV RNA The latter may have been due to an unrelated HIV vaccine
- the patient received two weeks into treatment in accordance with the
- an infusion of HIV virions may be any infusion of HIV virions.
- CD4 count It is well known that CD4 cell function, and not simply
- CD4 count plays an important role in immunocompetence.
- a flow cytometer will count any lymphocyte that bears the CD3
- T cell and CD4 markers as a CD4+ T lymphocyte. This includes
- the patient also had 900 CD8 cells and a total of 900 T cells, meaning
- CD4 + CD8 + thymocytes express only a few CD4 + CD8 + thymocytes.
- TCR T cell receptors
- HIV disease has been the subject of considerable debate and
- Lymphocytes is Increased During HIV-lnfection", Clin Exp Immunol..
- TcRgd + lymphocytes were found to be increased in the
- the patient whose results are shown in FIGURE 5(c) may have
- the present invention establishes that there are two distinct
- immunodeficiency may be reversible if the HIV-producing cells are
- Anti-adhesion antibodies can be used to neutralize HIV-producing cells
- ICAM-2 AND ICAM-3 monoclonal antibodies on CD4 + T lymphocyte
- ICAM-1 ICAM-1
- ICAM-2 ICAM-3
- Butini article included the hybridoma cell lines for TS1 /22 and
- CD4 + T cells remain completely viable until day ten after infection and showed only a minor depletion of CD4 + T cells
- HIV human immunodeficiency virus
- Molluscum contagiosum is a skin disease that is known to
- HIV human immunodeficiency virus
- the lesions caused by the disease may be excised
- the patient was a 45 year old male with advanced AIDS.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96921318A EP0831907A4 (en) | 1995-06-06 | 1996-06-06 | Method for treating molluscum contagiosum resulting from hiv infection |
AU62567/96A AU6256796A (en) | 1995-06-06 | 1996-06-06 | Method for treating molluscum contagiosum resulting from hiv infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46735695A | 1995-06-06 | 1995-06-06 | |
US08/467,356 | 1995-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996039187A1 true WO1996039187A1 (en) | 1996-12-12 |
Family
ID=23855366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/009192 WO1996039187A1 (en) | 1995-06-06 | 1996-06-06 | Method for treating molluscum contagiosum resulting from hiv infection |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0831907A4 (en) |
AU (1) | AU6256796A (en) |
WO (1) | WO1996039187A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990013281A2 (en) * | 1989-04-28 | 1990-11-15 | Baylor College Of Medicine | Method of suppressing hiv infection |
US5002869A (en) * | 1987-11-02 | 1991-03-26 | Dana-Farber Cancer Institute | Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5553290A (en) * | 1989-04-28 | 1990-11-29 | Baylor College Of Medicine | Dissemination of hiv-1 infected cells |
CA2140933A1 (en) * | 1992-08-21 | 1994-02-22 | Paula M. Jardieu | Method for treating an lfa-1 mediated disorder |
EP1438970B1 (en) * | 1993-03-19 | 2008-09-17 | ALLEN, D. Allen | Methods for inhibiting HIV associated disease using monoclonal antibodies directed against anti-self cytotoxic t-cells |
AU2248395A (en) * | 1994-04-15 | 1995-11-10 | Allen D. Allen | Method of treating hiv infection using antibodies against cytotoxic t-cells and thymic humoral factor |
-
1996
- 1996-06-06 WO PCT/US1996/009192 patent/WO1996039187A1/en not_active Application Discontinuation
- 1996-06-06 AU AU62567/96A patent/AU6256796A/en not_active Abandoned
- 1996-06-06 EP EP96921318A patent/EP0831907A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5002869A (en) * | 1987-11-02 | 1991-03-26 | Dana-Farber Cancer Institute | Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes |
WO1990013281A2 (en) * | 1989-04-28 | 1990-11-15 | Baylor College Of Medicine | Method of suppressing hiv infection |
Non-Patent Citations (5)
Title |
---|
ARCH. VIROL., 1995, Vol. 140, SCHEGLOVITOVA et al., "Antibody to ICAM-1 Mediates Enhancement of HIV-1 Infection of Human Endothelial Cells", pages 951-958. * |
CELLULAR IMMUNOLOGY, 1994, Vol. 156, DEZZUTTI et al., "Modulation of HTLV-II-Associated Spontaneous Lymphocyte Proliferation by Beta 2 Integrin CD11a/CD18 Involves Interaction with its Cognate Ligand, CD54", pages 113-123. * |
J. EXP. MED., April 1989, Vol. 169, TSUBOTA et al., "A Cytotoxic T Lymphocyte Inhibits Acquired Immunodeficiency Syndrome Virus Replication in Pirepheral Blood Lymphocytes", pages 1421-1434. * |
J. EXP. MED., February 1994, Vol. 179, DE FOUGEROLLES et al., "Characterization of the Function of Intercellular Adhesion Molecule (ICAM)-3 and Comparison with ICAM-1 and ICAM-2 in Immune Responses", pages 619-629. * |
See also references of EP0831907A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP0831907A4 (en) | 2005-05-04 |
EP0831907A1 (en) | 1998-04-01 |
AU6256796A (en) | 1996-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ahmed et al. | T4+ T helper cell function in vivo: differential requirement for induction of antiviral cytotoxic T-cell and antibody responses | |
Siegal et al. | Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity. | |
Dahl | Suppression of immunity and inflammation by products produced by dermatophytes | |
Jamieson et al. | Effective clearance of a persistent viral infection requires cooperation between virus-specific Lyt2+ T cells and nonspecific bone marrow-derived cells | |
Jacobson et al. | Impaired measles virus-specific cytotoxic T cell responses in multiple sclerosis. | |
AU670024B2 (en) | Methods of treating or preventing autoimmune uveoretinitis in mammals | |
Morris Jones et al. | The response of γδ T cells to Plasmodium falciparum is dependent on activated CD4+ T cells and the recognition of MHC class I molecules | |
CA2425086A1 (en) | Method of increasing the delayed-type hypersensitivity response by infusing lfa-1 specific antibodies | |
US6534057B2 (en) | Method increasing the delayed-type hypersensitivity response by infusing LFA-1-specific antibodies | |
Clarke et al. | The effects of prednisolone in leucocyte function in man. A double blind controlled study | |
Cole et al. | Immunosuppressive properties of the Mycoplasma arthritidis T-cell mitogen in vivo: inhibition of proliferative responses to T-cell mitogens | |
US5178858A (en) | Method for prevention of graft versus host disease | |
AU2003203742B2 (en) | Method increasing the delayed-type hypersensitivity response by infusing LFA-1-specific antibodies | |
WO1995028176A1 (en) | Method of treating hiv infection using antibodies against cytotoxic t-cells and thymic humoral factor | |
EP0831907A1 (en) | Method for treating molluscum contagiosum resulting from hiv infection | |
US5651970A (en) | Method for inhibiting disease associated with the human immunodeficiency virus through the use of monoclonal antibodies directed against anti-self cytotoxic T-lymphocytes or their lytics | |
Hassell et al. | MHC restriction of synovial fluid lymphocyte responses to the triggering organism in reactive arthritis. Absence of a class I-restricted response | |
CN111214650A (en) | Application of dissociation factor of HIV antigen-receptor trimer complex | |
Willenborg et al. | The effect of sea star coelomocyte extract on cell-mediated resistance to Listeria monocytogenes in mice | |
Ofosu-Appiah et al. | Characterization of a T suppressor cell line that downgrades experimental allergic encephalomyelitis in mice | |
EP0319333B1 (en) | Method for the prevention of graft versus host disease | |
TAGAWA et al. | Phenotypical heterogeneity of Japanese adult T‐cell leukaemia | |
Deem et al. | The CD8+ Leu-7+ subset of T cells in Crohn's disease: distinction between cytotoxic and covert suppressor functions | |
Takayanagi et al. | Trypanosoma gambiense: enhancement of agglutinin and protection in subpopulations by immune spleen cells | |
Fahey et al. | Immunity to Plasmodium yoelii: kinetics of the generation of T and B lymphocytes that passively transfer protective immunity against virulent challenge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996921318 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996921318 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996921318 Country of ref document: EP |